We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CHMT
1326
DELISTED
Chemtura Corporation
CHMT
| $2.96M | 0.01% |
88,616
+4,439
| +5% | +$147K |
|
1327
Repligen
RGEN
$7.96B
| $2.96M | 0.01% |
83,987
+19,046
| +29% | +$603K |
|
1328
Paycom
PAYC
$7.64B
| $2.95M | 0.01% |
51,259
+1,652
| +3% | +$85.7K |
|
1329
Dolby
DLB
$5.56B
| $2.95M | 0.01% |
56,220
-1,048
| -2% | -$51.9K |
|
1330
RBC Bearings
RBC
$17.4B
| $2.93M | 0.01% |
30,224
+869
| +3% | +$80.6K |
|
1331
Supernus Pharmaceuticals
SUPN
$2.59B
| $2.93M | 0.01% |
93,619
+28,420
| +44% | +$762K |
|
1332
Aaon
AAON
$7.3B
| $2.93M | 0.01% |
124,289
+31,848
| +34% | +$731K |
|
1333
Meritage Homes
MTH
$4.58B
| $2.92M | 0.01% |
158,928
+35,638
| +29% | +$638K |
|
|
SEM
1334
DELISTED
Select Medical
SEM
| $2.92M | 0.01% |
406,113
+119,584
| +42% | +$867K |
|
|
ARGO
1335
DELISTED
Argo Group International Holdings, Ltd.
ARGO
| $2.92M | 0.01% |
49,516
+1,369
| +3% | +$78.6K |
|
1336
Green Dot
GDOT
$743M
| $2.91M | 0.01% |
87,313
+25,543
| +41% | +$724K |
|
|
LGF.B
1337
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $2.91M | 0.01% |
119,426
-5,188
| -4% | -$132K |
|
1338
Rambus
RMBS
$9.87B
| $2.91M | 0.01% |
221,403
+59,307
| +37% | +$779K |
|
1339
Designer Brands
DBI
$307M
| $2.91M | 0.01% |
140,603
+56,140
| +66% | +$1.16M |
|
|
ABAX
1340
DELISTED
Abaxis Inc
ABAX
| $2.89M | 0.01% |
59,636
+8,358
| +16% | +$415K |
|
|
P
1341
DELISTED
Pandora Media Inc
P
| $2.89M | 0.01% |
244,675
+17,469
| +8% | +$219K |
|
1342
CONMED
CNMD
$1.39B
| $2.89M | 0.01% |
65,005
+13,928
| +27% | +$599K |
|
1343
Bruker
BRKR
$9.57B
| $2.88M | 0.01% |
123,641
+783
| +0.6% | +$18.4K |
|
|
CLVS
1344
DELISTED
Clovis Oncology, Inc.
CLVS
| $2.87M | 0.01% |
45,131
+7,196
| +19% | +$437K |
|
1345
BGC Group
BGC
$5.52B
| $2.85M | 0.01% |
389,420
+13,150
| +3% | +$94.5K |
|
|
CPE
1346
DELISTED
Callon Petroleum Company
CPE
| $2.85M | 0.01% |
21,618
+3,513
| +19% | +$485K |
|
1347
Gentherm
THRM
$1.24B
| $2.84M | 0.01% |
72,445
+20,316
| +39% | +$727K |
|
|
DCH
1348
Dauch Corp
DCH
$1.34B
| $2.84M | 0.01% |
151,342
+40,459
| +36% | +$807K |
|
1349
Generac Holdings
GNRC
$11.6B
| $2.84M | 0.01% |
76,204
+3,304
| +5% | +$131K |
|
1350
Fabrinet
FN
$15.6B
| $2.83M | 0.01% |
67,251
+20,729
| +45% | +$861K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.